Insulet Corporation - Common Stock (PODD)
257.56
+11.22 (4.56%)
NASDAQ · Last Trade: Feb 18th, 4:09 PM EST
Detailed Quote
| Previous Close | 246.34 |
|---|---|
| Open | 266.00 |
| Bid | 257.40 |
| Ask | 257.73 |
| Day's Range | 256.62 - 275.10 |
| 52 Week Range | 230.05 - 354.88 |
| Volume | 1,678,122 |
| Market Cap | 17.74B |
| PE Ratio (TTM) | 74.87 |
| EPS (TTM) | 3.4 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,104,153 |
Chart
About Insulet Corporation - Common Stock (PODD)
Insulet Corp is a healthcare company specializing in the development and manufacturing of innovative insulin delivery systems for individuals with diabetes. The company is best known for its Omnipod Insulin Management System, a tubeless, waterproof device that allows users to deliver insulin discreetly and conveniently without the need for traditional syringes or infusion sets. Insulet is committed to enhancing the quality of life for diabetes patients by providing advanced technology solutions that simplify insulin management, improve glycemic control, and promote independence in self-care. Through ongoing research and development, Insulet aims to lead the way in diabetes management innovation. Read More
News & Press Releases
Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) jumped 5.6% in the afternoon session after the company posted strong fourth-quarter 2025 financial results that beat Wall Street's expectations.
Via StockStory · February 18, 2026
Insulet Corporation (NASDAQ:PODD) delivered a commanding performance in its fourth-quarter earnings report released today, February 18, 2026. The medical device leader announced an adjusted earnings per share (EPS) of $1.55, significantly outstripping Wall Street’s consensus estimate of $1.46. Revenue for the quarter reached $783.8 million,
Via MarketMinute · February 18, 2026
What's going on in today's session: S&P500 moverschartmill.com
Via Chartmill · February 18, 2026
Insulet Corp. (NASDAQ:PODD) Reports Strong Q4 Earnings Beat Amid Mixed 2026 Guidancechartmill.com
Via Chartmill · February 18, 2026
Insulet Corp (NASDAQ:PODD): A Prime GARP Candidate in Diabetes Carechartmill.com
Via Chartmill · February 17, 2026
Insulet Corp (NASDAQ:PODD) Matches Key Growth Rules in Navellier's "Little Book" Strategychartmill.com
Via Chartmill · February 4, 2026
Insulet Corp (NASDAQ:PODD) Passes Key Growth Screen with Strong Momentumchartmill.com
Via Chartmill · January 14, 2026
Wednesday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Via Chartmill · February 18, 2026
What's going on in today's pre-market session: S&P500 moverschartmill.com
Via Chartmill · February 18, 2026
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 31.2% year on year to $783.8 million. The company expects next quarter’s revenue to be around $716.9 million, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 6% above analysts’ consensus estimates.
Via StockStory · February 18, 2026
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2025.
By Insulet Corporation · Via Business Wire · February 18, 2026
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting earnings this Wednesday morning. Here’s what to look for.
Via StockStory · February 16, 2026
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion.
The best of these businesses balance profitability with reinvestment, setting themselves up for long-term success.
Via StockStory · February 10, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via StockStory · February 8, 2026
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its transformative Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East – including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates (UAE). The Company is making the announcement at the 16th edition of the Emirates Diabetes and Endocrine Congress (EDEC) in Dubai.
By Insulet Corporation · Via Business Wire · February 5, 2026
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Via StockStory · February 1, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · January 23, 2026
Which S&P500 stocks are moving on Friday?chartmill.com
Via Chartmill · January 23, 2026
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Via StockStory · January 20, 2026
Join us as we evaluate Insulet's potential in the diabetes management market. With a unique product offering and strong growth, could this stock be your next big investment?
Via The Motley Fool · January 20, 2026
Today’s Date: January 9, 2026 Introduction In the rapidly evolving landscape of medical technology, few companies have managed to fundamentally reshape a multi-decade standard of care as successfully as Insulet Corporation (NASDAQ: PODD). Historically, insulin delivery was synonymous with either multiple daily injections (MDI) or cumbersome, tubed mechanical pumps. Insulet disrupted this paradigm with the [...]
Via PredictStreet · January 9, 2026
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Via Chartmill · January 9, 2026
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
By Insulet Corporation · Via Business Wire · January 9, 2026